Alfonso Quintás‐Cardama

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Alfonso Quintás‐Cardama, Kris Vaddi, Phillip Liu et al. · Blood · 2010 · 827 citations

Medicine, Hematology, Pharmacology +11

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Taghi Manshouri et al. · Journal of Clinical Oncology · 2009 · 416 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +13

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Susan O’Brien et al. · Journal of Clinical Oncology · 2007 · 392 citations

Medicine, Pharmacology, Pharmacotherapy +8

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Hagop M. Kantarjian, Susan O’Brien, Elias Jabbour et al. · Blood · 2012 · 338 citations · Full text

Medicine, Hematology, Oncology +5

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

Weiguo Zhang, Marina Konopleva, Yue-Xi Shi et al. · JNCI Journal of the National Cancer Institute · 2008 · 338 citations · Full text

Medicine, Oncology, Pharmacology +17